NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

March 17, 2016

Stacy Loeb, MD, discusses how screening tests for prostate cancer work, what their benefits are, and what urological specialists need to know in order to best utilize them.

March 15, 2016

Timothy W. Strawderman, PhD, has been named the new Executive Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, an NCI-designated cancer center.

March 14, 2016

Internationally renowned surgeon and scientist Douglas A. Levine, MD, FACOG, FACS, whose seminal biomarker research has helped to advance early detection and treatment of ovarian cancer, will join the faculty of NYU Langone Medical Center as director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology.

February 15, 2016

Arjun V. Balar, MD, discusses the phase II data demonstrating the efficacy of atezolizumab as a single agent, its potential as part of combination regimens, and planned clinical trials looking at immunotherapy in patients with metastatic bladder cancer.

February 09, 2016

Jeffrey S. Weber, MD, PhD, discusses the role that melanoma specialists can play in educating other oncologists, immunotherapy use for BRAF-mutated patients with melanoma, and how the use of chemotherapy may evolve as immunotherapies take the forefront.

February 03, 2016

Experimental drugs that alter cell metabolism also halted tumor growth and extended survival in mice with cancers caused by a gene mutated in several types of brain tumors.

February 03, 2016

Study identifies a potential drug target for inhibiting common radiation-induced fibrosis.

February 03, 2016

New study shows blood test does better job than current standard test at tracking severity and potential spread of metastatic melanoma.

February 03, 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

February 03, 2016

Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual’s survival and determine which patients require closer monitoring in the years following surgery.

February 03, 2016

NYU Langone Medical Center first in Northeast to utilize new technology allowing surgeons to destroy only suspicious prostate tissue.

January 18, 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

December 31, 2015

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

December 23, 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

December 04, 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the potential for immunotherapy in colorectal cancer with mismatch repair deficiency.

November 25, 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, compares the efficacy of dabrafenib plus trametinib versus vemurafenib plus cobimetinib.

November 24, 2015

The FDA has expanded the approval for single-agent nivolumab (Opdivo) to include the frontline treatment of patients with BRAF wild-type advanced melanoma.

November 05, 2015

Combinations of targeted therapies continue to advance toward full regulatory approval for patients with metastatic or unresected melanoma, given the substantial benefits seen with these agents.

October 16, 2015

Internationally renowned clinician-scientist Alec Kimmelman, MD, PhD, has been named Chair of the Department of Radiation Oncology at NYU Langone Medical Center. His appointment is effective February 1, 2016.

October 14, 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.